| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammography | 92 | 2024 | 1045 | 10.290 |
Why?
|
| Ultrasonography, Mammary | 38 | 2024 | 386 | 8.560 |
Why?
|
| Breast Neoplasms | 137 | 2024 | 16196 | 6.450 |
Why?
|
| Breast Diseases | 14 | 2021 | 206 | 4.210 |
Why?
|
| Breast | 46 | 2024 | 1379 | 3.500 |
Why?
|
| Radiographic Image Enhancement | 18 | 2014 | 410 | 2.410 |
Why?
|
| Magnetic Resonance Imaging | 47 | 2024 | 7927 | 2.380 |
Why?
|
| Mass Screening | 19 | 2024 | 1553 | 2.250 |
Why?
|
| Image-Guided Biopsy | 7 | 2020 | 337 | 1.810 |
Why?
|
| Diagnostic Imaging | 7 | 2024 | 1178 | 1.770 |
Why?
|
| Biopsy, Needle | 22 | 2019 | 1401 | 1.600 |
Why?
|
| Surgical Instruments | 4 | 2023 | 139 | 1.590 |
Why?
|
| Cicatrix | 2 | 2024 | 186 | 1.410 |
Why?
|
| Triple Negative Breast Neoplasms | 11 | 2024 | 1372 | 1.390 |
Why?
|
| Image Interpretation, Computer-Assisted | 7 | 2018 | 593 | 1.370 |
Why?
|
| Lymph Nodes | 11 | 2023 | 3067 | 1.340 |
Why?
|
| Mastectomy, Segmental | 9 | 2021 | 1047 | 1.330 |
Why?
|
| Artifacts | 7 | 2023 | 537 | 1.310 |
Why?
|
| Female | 172 | 2024 | 148622 | 1.220 |
Why?
|
| Carcinoma, Lobular | 9 | 2024 | 617 | 1.200 |
Why?
|
| Lymphatic Metastasis | 13 | 2023 | 4967 | 1.190 |
Why?
|
| Calcinosis | 13 | 2011 | 432 | 1.180 |
Why?
|
| Carcinoma, Ductal, Breast | 13 | 2018 | 1233 | 1.180 |
Why?
|
| Multimodal Imaging | 5 | 2020 | 553 | 1.170 |
Why?
|
| Humans | 238 | 2024 | 271060 | 1.100 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 10 | 2020 | 693 | 1.040 |
Why?
|
| Neoadjuvant Therapy | 22 | 2024 | 5206 | 0.960 |
Why?
|
| Biopsy | 13 | 2023 | 3544 | 0.950 |
Why?
|
| Early Detection of Cancer | 7 | 2024 | 1331 | 0.940 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 10 | 2013 | 379 | 0.940 |
Why?
|
| Archives | 1 | 2024 | 5 | 0.930 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2024 | 17 | 0.920 |
Why?
|
| Vascular Neoplasms | 2 | 2023 | 113 | 0.840 |
Why?
|
| Radiology Information Systems | 4 | 2015 | 118 | 0.810 |
Why?
|
| Hemangioma | 1 | 2023 | 160 | 0.770 |
Why?
|
| Contrast Media | 8 | 2020 | 1510 | 0.760 |
Why?
|
| Preoperative Care | 6 | 2022 | 1547 | 0.750 |
Why?
|
| Mastitis | 1 | 2020 | 12 | 0.740 |
Why?
|
| Granulomatous Mastitis | 1 | 2020 | 9 | 0.740 |
Why?
|
| Genes, BRCA1 | 3 | 2020 | 388 | 0.730 |
Why?
|
| Angiomatosis | 2 | 2021 | 27 | 0.720 |
Why?
|
| Breast Neoplasms, Male | 3 | 2018 | 231 | 0.720 |
Why?
|
| Retrospective Studies | 46 | 2024 | 39720 | 0.720 |
Why?
|
| Radiology | 9 | 2024 | 428 | 0.710 |
Why?
|
| Hemangiosarcoma | 1 | 2023 | 237 | 0.710 |
Why?
|
| Carcinoma, Papillary | 3 | 2018 | 581 | 0.700 |
Why?
|
| Middle Aged | 95 | 2024 | 90103 | 0.680 |
Why?
|
| Genes, BRCA2 | 2 | 2020 | 310 | 0.670 |
Why?
|
| Neoplasm Staging | 20 | 2024 | 13979 | 0.660 |
Why?
|
| Axilla | 7 | 2023 | 924 | 0.650 |
Why?
|
| Diagnosis, Differential | 16 | 2020 | 4886 | 0.640 |
Why?
|
| Sensitivity and Specificity | 21 | 2020 | 5187 | 0.640 |
Why?
|
| Phyllodes Tumor | 2 | 2018 | 65 | 0.640 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 185 | 0.630 |
Why?
|
| Hyperplasia | 6 | 2021 | 581 | 0.620 |
Why?
|
| Machine Learning | 1 | 2021 | 356 | 0.610 |
Why?
|
| Adult | 85 | 2024 | 81619 | 0.610 |
Why?
|
| Image Enhancement | 4 | 2017 | 555 | 0.600 |
Why?
|
| Gadolinium DTPA | 1 | 2018 | 173 | 0.590 |
Why?
|
| Ultrasonography, Interventional | 2 | 2018 | 417 | 0.560 |
Why?
|
| Stereotaxic Techniques | 3 | 2017 | 183 | 0.560 |
Why?
|
| Breast Density | 1 | 2016 | 20 | 0.550 |
Why?
|
| Ultrasonography | 19 | 2023 | 1938 | 0.550 |
Why?
|
| Aged | 64 | 2024 | 73250 | 0.530 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 121 | 0.530 |
Why?
|
| Molecular Imaging | 1 | 2017 | 187 | 0.500 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 878 | 0.480 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2014 | 916 | 0.470 |
Why?
|
| Mobile Health Units | 1 | 2013 | 35 | 0.450 |
Why?
|
| Congresses as Topic | 1 | 2015 | 296 | 0.450 |
Why?
|
| Radiography | 23 | 2024 | 1988 | 0.430 |
Why?
|
| Radiographic Magnification | 3 | 2009 | 15 | 0.430 |
Why?
|
| Cone-Beam Computed Tomography | 3 | 2009 | 210 | 0.420 |
Why?
|
| Tomography, X-Ray Computed | 32 | 2020 | 7786 | 0.410 |
Why?
|
| Formative Feedback | 2 | 2023 | 33 | 0.410 |
Why?
|
| Algorithms | 10 | 2011 | 3907 | 0.410 |
Why?
|
| X-Ray Film | 2 | 2009 | 31 | 0.410 |
Why?
|
| Subtraction Technique | 2 | 2002 | 145 | 0.400 |
Why?
|
| Workload | 2 | 2013 | 199 | 0.390 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 166 | 0.390 |
Why?
|
| Guideline Adherence | 2 | 2017 | 647 | 0.390 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2012 | 106 | 0.390 |
Why?
|
| Osteosarcoma | 1 | 2019 | 948 | 0.390 |
Why?
|
| ROC Curve | 14 | 2024 | 1237 | 0.380 |
Why?
|
| Attitude of Health Personnel | 3 | 2015 | 918 | 0.380 |
Why?
|
| Observer Variation | 10 | 2014 | 720 | 0.380 |
Why?
|
| Biopsy, Large-Core Needle | 3 | 2020 | 139 | 0.370 |
Why?
|
| Patient Selection | 3 | 2018 | 2041 | 0.370 |
Why?
|
| Papilloma, Intraductal | 2 | 2020 | 17 | 0.360 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 186 | 0.360 |
Why?
|
| Efficiency, Organizational | 2 | 2009 | 94 | 0.350 |
Why?
|
| Monitoring, Intraoperative | 1 | 2011 | 264 | 0.350 |
Why?
|
| Ultrasonography, Doppler, Color | 2 | 2007 | 108 | 0.350 |
Why?
|
| Liver Neoplasms | 5 | 2020 | 4795 | 0.350 |
Why?
|
| Fibroma | 2 | 2006 | 87 | 0.330 |
Why?
|
| Radiologists | 3 | 2022 | 178 | 0.320 |
Why?
|
| Fat Necrosis | 1 | 2009 | 59 | 0.320 |
Why?
|
| Task Performance and Analysis | 1 | 2009 | 137 | 0.310 |
Why?
|
| Precancerous Conditions | 3 | 2011 | 1066 | 0.310 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 2007 | 235 | 0.300 |
Why?
|
| Sentinel Lymph Node Biopsy | 4 | 2021 | 1449 | 0.290 |
Why?
|
| Artificial Intelligence | 2 | 2024 | 438 | 0.290 |
Why?
|
| Lymphoma, B-Cell | 3 | 2011 | 935 | 0.280 |
Why?
|
| Monte Carlo Method | 3 | 2009 | 697 | 0.280 |
Why?
|
| Reproducibility of Results | 15 | 2024 | 6187 | 0.280 |
Why?
|
| Phantoms, Imaging | 9 | 2023 | 1330 | 0.280 |
Why?
|
| Chondroblastoma | 1 | 2006 | 15 | 0.270 |
Why?
|
| Follow-Up Studies | 11 | 2021 | 15249 | 0.270 |
Why?
|
| Ilium | 1 | 2006 | 54 | 0.260 |
Why?
|
| Inflammatory Breast Neoplasms | 2 | 2023 | 528 | 0.250 |
Why?
|
| Mammary Glands, Human | 2 | 2008 | 185 | 0.250 |
Why?
|
| Clinical Competence | 5 | 2021 | 1323 | 0.250 |
Why?
|
| Sacrum | 1 | 2006 | 139 | 0.250 |
Why?
|
| Fibromatosis, Aggressive | 2 | 2004 | 110 | 0.250 |
Why?
|
| Aortic Rupture | 2 | 1996 | 116 | 0.250 |
Why?
|
| Lipoma | 2 | 2004 | 94 | 0.250 |
Why?
|
| Spirituality | 1 | 2006 | 129 | 0.240 |
Why?
|
| Prospective Studies | 11 | 2024 | 13375 | 0.240 |
Why?
|
| Liposarcoma | 2 | 2000 | 247 | 0.240 |
Why?
|
| Radius | 1 | 2024 | 44 | 0.240 |
Why?
|
| Mesentery | 1 | 2004 | 74 | 0.230 |
Why?
|
| Scotland | 1 | 2024 | 43 | 0.230 |
Why?
|
| Mastectomy | 5 | 2022 | 1547 | 0.230 |
Why?
|
| Diagnosis, Computer-Assisted | 4 | 2013 | 169 | 0.220 |
Why?
|
| Positron-Emission Tomography | 5 | 2020 | 2198 | 0.220 |
Why?
|
| Aged, 80 and over | 20 | 2024 | 30966 | 0.220 |
Why?
|
| Adenocarcinoma | 3 | 2020 | 7936 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 4 | 2017 | 2428 | 0.210 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2022 | 341 | 0.210 |
Why?
|
| Personnel Selection | 1 | 2024 | 85 | 0.210 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2017 | 1322 | 0.210 |
Why?
|
| Communication | 2 | 2021 | 856 | 0.210 |
Why?
|
| Intestinal Neoplasms | 1 | 2004 | 201 | 0.210 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 1996 | 348 | 0.200 |
Why?
|
| Radiography, Thoracic | 3 | 2002 | 473 | 0.200 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2002 | 57 | 0.200 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2020 | 1259 | 0.200 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2024 | 295 | 0.190 |
Why?
|
| Adenoma | 2 | 2004 | 741 | 0.190 |
Why?
|
| Skin Neoplasms | 1 | 2018 | 4838 | 0.190 |
Why?
|
| Radiation Dosage | 6 | 2014 | 1043 | 0.190 |
Why?
|
| Phthalazines | 2 | 2022 | 263 | 0.190 |
Why?
|
| Esthetics | 1 | 2021 | 116 | 0.190 |
Why?
|
| Mentoring | 1 | 2022 | 98 | 0.180 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 1323 | 0.180 |
Why?
|
| United States | 10 | 2024 | 16011 | 0.180 |
Why?
|
| Pyelonephritis | 2 | 1995 | 48 | 0.180 |
Why?
|
| Leiomyoma | 1 | 2001 | 161 | 0.180 |
Why?
|
| Lung Diseases | 4 | 1999 | 753 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2023 | 16603 | 0.170 |
Why?
|
| Learning | 1 | 2023 | 432 | 0.170 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 407 | 0.170 |
Why?
|
| Mediastinal Neoplasms | 2 | 2000 | 429 | 0.170 |
Why?
|
| Nipple Discharge | 1 | 2019 | 8 | 0.170 |
Why?
|
| Whole Body Imaging | 1 | 2020 | 113 | 0.170 |
Why?
|
| Emphysema | 2 | 1995 | 88 | 0.170 |
Why?
|
| Feasibility Studies | 6 | 2017 | 2347 | 0.160 |
Why?
|
| Margins of Excision | 1 | 2021 | 314 | 0.160 |
Why?
|
| Oncolytic Virotherapy | 1 | 2021 | 235 | 0.160 |
Why?
|
| Advisory Committees | 1 | 2020 | 210 | 0.160 |
Why?
|
| Bone Neoplasms | 2 | 2015 | 2667 | 0.160 |
Why?
|
| Male | 46 | 2020 | 128513 | 0.160 |
Why?
|
| Hamartoma | 1 | 1999 | 87 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2023 | 3972 | 0.160 |
Why?
|
| Prognosis | 15 | 2022 | 22464 | 0.150 |
Why?
|
| Biological Products | 1 | 2021 | 316 | 0.150 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 165 | 0.150 |
Why?
|
| Data Display | 3 | 2013 | 52 | 0.150 |
Why?
|
| Area Under Curve | 3 | 2013 | 724 | 0.150 |
Why?
|
| Peritoneal Neoplasms | 1 | 2004 | 851 | 0.140 |
Why?
|
| Treatment Outcome | 14 | 2024 | 33850 | 0.140 |
Why?
|
| Vacuum | 3 | 2012 | 42 | 0.140 |
Why?
|
| Connecticut | 1 | 2016 | 37 | 0.140 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 323 | 0.140 |
Why?
|
| Uterine Neoplasms | 1 | 2001 | 580 | 0.140 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 1999 | 508 | 0.130 |
Why?
|
| Decision Making | 2 | 2016 | 1242 | 0.130 |
Why?
|
| Paclitaxel | 4 | 2020 | 2099 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 14682 | 0.130 |
Why?
|
| Tumor Burden | 2 | 2021 | 2034 | 0.130 |
Why?
|
| Kidney | 5 | 1996 | 2266 | 0.130 |
Why?
|
| Fluorouracil | 4 | 2020 | 1987 | 0.130 |
Why?
|
| Surveys and Questionnaires | 7 | 2024 | 5908 | 0.130 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 1995 | 7 | 0.130 |
Why?
|
| Coronary Artery Bypass | 1 | 1999 | 568 | 0.130 |
Why?
|
| Lymph Node Excision | 4 | 2022 | 2044 | 0.130 |
Why?
|
| Coronary Disease | 1 | 1999 | 776 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 4 | 2018 | 4069 | 0.120 |
Why?
|
| Quality Assurance, Health Care | 1 | 1999 | 612 | 0.120 |
Why?
|
| Sentinel Lymph Node | 1 | 2017 | 229 | 0.120 |
Why?
|
| Age Distribution | 2 | 2015 | 728 | 0.120 |
Why?
|
| Incidental Findings | 1 | 2016 | 282 | 0.120 |
Why?
|
| Nephroma, Mesoblastic | 1 | 1994 | 15 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2015 | 1708 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 966 | 0.110 |
Why?
|
| Urinary Bladder Diseases | 1 | 1994 | 54 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 559 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2015 | 423 | 0.110 |
Why?
|
| Genetic Therapy | 1 | 2021 | 1732 | 0.110 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 1994 | 299 | 0.110 |
Why?
|
| Guidelines as Topic | 1 | 2015 | 371 | 0.110 |
Why?
|
| Combined Modality Therapy | 8 | 2021 | 9045 | 0.110 |
Why?
|
| Physical Examination | 1 | 2015 | 303 | 0.110 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 908 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 1996 | 1068 | 0.110 |
Why?
|
| Appointments and Schedules | 1 | 2013 | 98 | 0.110 |
Why?
|
| Texas | 2 | 2018 | 6414 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2022 | 10351 | 0.110 |
Why?
|
| Trastuzumab | 1 | 2015 | 736 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2018 | 2286 | 0.100 |
Why?
|
| Cyclophosphamide | 4 | 2020 | 3231 | 0.100 |
Why?
|
| Computer Simulation | 3 | 2009 | 1522 | 0.100 |
Why?
|
| Mammaplasty | 2 | 2015 | 715 | 0.100 |
Why?
|
| Risk Factors | 3 | 2024 | 17829 | 0.100 |
Why?
|
| Forecasting | 2 | 2013 | 707 | 0.100 |
Why?
|
| Survival Rate | 6 | 2018 | 12518 | 0.100 |
Why?
|
| X-Ray Intensifying Screens | 3 | 2006 | 35 | 0.100 |
Why?
|
| Scattering, Radiation | 2 | 2009 | 334 | 0.100 |
Why?
|
| Radiopharmaceuticals | 3 | 2013 | 1338 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 3 | 2023 | 2648 | 0.100 |
Why?
|
| Carcinoma in Situ | 3 | 2010 | 495 | 0.100 |
Why?
|
| Feedback | 2 | 2023 | 227 | 0.100 |
Why?
|
| Premedication | 1 | 1991 | 133 | 0.090 |
Why?
|
| Kidney Neoplasms | 3 | 1997 | 3145 | 0.090 |
Why?
|
| Time Factors | 7 | 2010 | 13112 | 0.090 |
Why?
|
| Endometriosis | 1 | 1994 | 235 | 0.090 |
Why?
|
| Tamoxifen | 1 | 1995 | 907 | 0.090 |
Why?
|
| Pregnancy | 4 | 2015 | 8096 | 0.090 |
Why?
|
| False Negative Reactions | 3 | 2017 | 294 | 0.090 |
Why?
|
| Doxorubicin | 4 | 2007 | 3138 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2011 | 315 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2022 | 2852 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 853 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2021 | 1432 | 0.090 |
Why?
|
| Prostheses and Implants | 2 | 2007 | 294 | 0.090 |
Why?
|
| Spondylitis, Ankylosing | 1 | 1989 | 29 | 0.090 |
Why?
|
| Erythropoietin | 1 | 1991 | 218 | 0.090 |
Why?
|
| Receptors, Progesterone | 2 | 2018 | 1646 | 0.090 |
Why?
|
| Pattern Recognition, Automated | 1 | 2010 | 125 | 0.080 |
Why?
|
| Multiple Sclerosis | 2 | 1990 | 376 | 0.080 |
Why?
|
| Pandemics | 3 | 2024 | 1597 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 880 | 0.080 |
Why?
|
| Aortic Aneurysm | 1 | 1991 | 219 | 0.080 |
Why?
|
| Escherichia coli Infections | 2 | 1996 | 272 | 0.080 |
Why?
|
| Lung | 7 | 2002 | 3271 | 0.080 |
Why?
|
| Program Evaluation | 2 | 2022 | 613 | 0.080 |
Why?
|
| Radiography, Interventional | 3 | 1999 | 312 | 0.080 |
Why?
|
| Software | 3 | 2010 | 1360 | 0.080 |
Why?
|
| Receptors, Estrogen | 2 | 2018 | 2264 | 0.080 |
Why?
|
| Methotrexate | 1 | 2011 | 1027 | 0.080 |
Why?
|
| X-Rays | 4 | 2009 | 153 | 0.070 |
Why?
|
| Professional Competence | 1 | 2009 | 135 | 0.070 |
Why?
|
| User-Computer Interface | 1 | 2009 | 304 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 1992 | 961 | 0.070 |
Why?
|
| Linear Models | 1 | 2010 | 1092 | 0.070 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2010 | 698 | 0.070 |
Why?
|
| Tomography, Spiral Computed | 1 | 2007 | 128 | 0.070 |
Why?
|
| Radionuclide Imaging | 1 | 2008 | 658 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 7815 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 1011 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2015 | 9438 | 0.070 |
Why?
|
| Scrotum | 2 | 2004 | 60 | 0.070 |
Why?
|
| Genes, p53 | 1 | 2011 | 1133 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2022 | 514 | 0.070 |
Why?
|
| Rituximab | 1 | 2011 | 1589 | 0.070 |
Why?
|
| Medical Staff, Hospital | 1 | 2006 | 123 | 0.070 |
Why?
|
| Mutation | 2 | 2020 | 15861 | 0.060 |
Why?
|
| Dilatation, Pathologic | 1 | 2005 | 98 | 0.060 |
Why?
|
| Germ-Line Mutation | 2 | 2022 | 1069 | 0.060 |
Why?
|
| Young Adult | 4 | 2021 | 22062 | 0.060 |
Why?
|
| Genomics | 1 | 2016 | 2818 | 0.060 |
Why?
|
| Cytarabine | 1 | 2011 | 2014 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 1346 | 0.060 |
Why?
|
| Anemia | 1 | 1991 | 730 | 0.060 |
Why?
|
| Genital Diseases, Male | 1 | 2004 | 30 | 0.060 |
Why?
|
| Histiocytosis, Sinus | 1 | 2005 | 87 | 0.060 |
Why?
|
| Myoma | 1 | 2004 | 7 | 0.060 |
Why?
|
| Epidermal Cyst | 1 | 2004 | 47 | 0.060 |
Why?
|
| Leukemic Infiltration | 1 | 2004 | 73 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2016 | 6832 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2006 | 419 | 0.060 |
Why?
|
| Anisotropy | 1 | 2024 | 186 | 0.060 |
Why?
|
| Urography | 2 | 1994 | 57 | 0.060 |
Why?
|
| Contrast Sensitivity | 2 | 2013 | 67 | 0.050 |
Why?
|
| Education, Distance | 1 | 2024 | 100 | 0.050 |
Why?
|
| Drainage | 1 | 1995 | 448 | 0.050 |
Why?
|
| Necrosis | 2 | 2020 | 604 | 0.050 |
Why?
|
| Asbestosis | 1 | 2002 | 8 | 0.050 |
Why?
|
| Ergonomics | 1 | 2022 | 27 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2019 | 1618 | 0.050 |
Why?
|
| Lymphangioma, Cystic | 1 | 2001 | 23 | 0.050 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2003 | 115 | 0.050 |
Why?
|
| Pleural Diseases | 1 | 2002 | 58 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2009 | 2452 | 0.050 |
Why?
|
| Adolescent | 3 | 2018 | 32553 | 0.050 |
Why?
|
| Breast Implants | 2 | 2015 | 376 | 0.050 |
Why?
|
| Herpesvirus 1, Human | 1 | 2021 | 115 | 0.050 |
Why?
|
| Phenotype | 3 | 2018 | 6464 | 0.050 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2004 | 439 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2022 | 465 | 0.050 |
Why?
|
| Faculty, Medical | 1 | 2024 | 308 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2015 | 5683 | 0.050 |
Why?
|
| Intestine, Small | 1 | 2004 | 526 | 0.050 |
Why?
|
| Epirubicin | 1 | 2020 | 159 | 0.050 |
Why?
|
| Ketones | 1 | 2020 | 58 | 0.050 |
Why?
|
| Furans | 1 | 2020 | 103 | 0.050 |
Why?
|
| Nose Neoplasms | 1 | 2003 | 237 | 0.040 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 10250 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2006 | 2673 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 485 | 0.040 |
Why?
|
| Mentors | 1 | 2022 | 203 | 0.040 |
Why?
|
| Hepatic Artery | 1 | 2001 | 256 | 0.040 |
Why?
|
| Calibration | 2 | 2012 | 346 | 0.040 |
Why?
|
| Thymoma | 1 | 2003 | 253 | 0.040 |
Why?
|
| Pneumonia | 2 | 2004 | 798 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2022 | 1153 | 0.040 |
Why?
|
| Practice Management | 1 | 1999 | 9 | 0.040 |
Why?
|
| Epididymis | 2 | 1997 | 73 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 4982 | 0.040 |
Why?
|
| False Positive Reactions | 2 | 2012 | 373 | 0.040 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 10701 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 896 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2008 | 1462 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1992 | 2415 | 0.040 |
Why?
|
| Computer Communication Networks | 1 | 1999 | 50 | 0.040 |
Why?
|
| Technology, Radiologic | 1 | 1999 | 78 | 0.040 |
Why?
|
| Immobilization | 1 | 1999 | 91 | 0.040 |
Why?
|
| Anthracyclines | 1 | 2021 | 339 | 0.040 |
Why?
|
| Computer Systems | 1 | 1999 | 117 | 0.040 |
Why?
|
| Accreditation | 1 | 2019 | 136 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 1999 | 79 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 2003 | 420 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 595 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 1999 | 223 | 0.040 |
Why?
|
| Models, Biological | 2 | 2008 | 3226 | 0.040 |
Why?
|
| Workplace | 1 | 1999 | 92 | 0.040 |
Why?
|
| Efficiency | 2 | 2008 | 93 | 0.040 |
Why?
|
| Radiation Injuries | 2 | 2003 | 1472 | 0.040 |
Why?
|
| Parathyroid Neoplasms | 1 | 1999 | 187 | 0.040 |
Why?
|
| Neoplasm, Residual | 4 | 2007 | 1740 | 0.040 |
Why?
|
| Technetium | 1 | 2017 | 80 | 0.040 |
Why?
|
| Cauda Equina | 1 | 1997 | 13 | 0.040 |
Why?
|
| Taxoids | 1 | 2021 | 1008 | 0.040 |
Why?
|
| Mastectomy, Simple | 1 | 2017 | 59 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 370 | 0.040 |
Why?
|
| Rosaniline Dyes | 1 | 2017 | 109 | 0.040 |
Why?
|
| Adenoma, Villous | 1 | 1996 | 10 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1730 | 0.040 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 1996 | 8 | 0.030 |
Why?
|
| Lymphoid Tissue | 1 | 1997 | 102 | 0.030 |
Why?
|
| Internet | 1 | 2021 | 697 | 0.030 |
Why?
|
| Fournier Gangrene | 1 | 1996 | 4 | 0.030 |
Why?
|
| Remission Induction | 2 | 2015 | 3646 | 0.030 |
Why?
|
| Peroneal Nerve | 1 | 1996 | 5 | 0.030 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 1997 | 72 | 0.030 |
Why?
|
| Research Design | 1 | 2024 | 1573 | 0.030 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 1997 | 155 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 349 | 0.030 |
Why?
|
| Cholangitis | 1 | 1996 | 51 | 0.030 |
Why?
|
| Arteriovenous Malformations | 1 | 1996 | 67 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 516 | 0.030 |
Why?
|
| Fasciitis, Necrotizing | 1 | 1996 | 33 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 11776 | 0.030 |
Why?
|
| Pyelonephritis, Xanthogranulomatous | 1 | 1995 | 1 | 0.030 |
Why?
|
| Aspergillus fumigatus | 1 | 1996 | 138 | 0.030 |
Why?
|
| Adenoma, Liver Cell | 1 | 1995 | 16 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 429 | 0.030 |
Why?
|
| Age Factors | 4 | 1999 | 5487 | 0.030 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1999 | 441 | 0.030 |
Why?
|
| Hepatitis | 1 | 1996 | 94 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 1089 | 0.030 |
Why?
|
| Orbital Diseases | 1 | 1996 | 121 | 0.030 |
Why?
|
| Lung Diseases, Fungal | 1 | 1996 | 133 | 0.030 |
Why?
|
| Epididymitis | 1 | 1995 | 2 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 1070 | 0.030 |
Why?
|
| Thoracic Diseases | 1 | 1995 | 30 | 0.030 |
Why?
|
| Curriculum | 1 | 2021 | 914 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 1989 | 3236 | 0.030 |
Why?
|
| Mucormycosis | 1 | 1996 | 118 | 0.030 |
Why?
|
| Intraoperative Period | 2 | 2007 | 259 | 0.030 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 1996 | 76 | 0.030 |
Why?
|
| Captopril | 1 | 1994 | 37 | 0.030 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1995 | 75 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1996 | 237 | 0.030 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 1994 | 18 | 0.030 |
Why?
|
| Aspergillosis | 1 | 1996 | 249 | 0.030 |
Why?
|
| Tacrolimus | 1 | 1996 | 351 | 0.030 |
Why?
|
| Oropharynx | 1 | 1994 | 80 | 0.030 |
Why?
|
| Pulmonary Veins | 1 | 1996 | 180 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 517 | 0.030 |
Why?
|
| Cysts | 1 | 1996 | 208 | 0.030 |
Why?
|
| Duodenal Diseases | 1 | 1994 | 47 | 0.030 |
Why?
|
| Eosinophilic Granuloma | 1 | 1993 | 15 | 0.030 |
Why?
|
| Vasculitis | 1 | 1994 | 77 | 0.030 |
Why?
|
| Sarcoidosis | 1 | 1995 | 114 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1995 | 190 | 0.030 |
Why?
|
| Diaphragm | 1 | 1995 | 187 | 0.030 |
Why?
|
| Neurilemmoma | 1 | 1994 | 134 | 0.030 |
Why?
|
| Cystoscopy | 1 | 1994 | 92 | 0.030 |
Why?
|
| Equipment Failure Analysis | 2 | 2006 | 327 | 0.030 |
Why?
|
| Abscess | 1 | 1995 | 191 | 0.030 |
Why?
|
| Kidney Diseases, Cystic | 1 | 1993 | 66 | 0.030 |
Why?
|
| Testicular Neoplasms | 1 | 1997 | 554 | 0.030 |
Why?
|
| Liquid Crystals | 1 | 2012 | 3 | 0.030 |
Why?
|
| Silicone Elastomers | 1 | 1993 | 54 | 0.030 |
Why?
|
| Colitis | 1 | 1996 | 344 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2009 | 1150 | 0.030 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 1994 | 125 | 0.030 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1995 | 383 | 0.030 |
Why?
|
| Trachea | 1 | 1994 | 290 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 1820 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 1996 | 520 | 0.030 |
Why?
|
| Amyloidosis | 1 | 1994 | 186 | 0.030 |
Why?
|
| Echo-Planar Imaging | 1 | 1993 | 74 | 0.030 |
Why?
|
| Hypertrophy | 1 | 1992 | 160 | 0.030 |
Why?
|
| Floxuridine | 1 | 1992 | 41 | 0.030 |
Why?
|
| Length of Stay | 1 | 1999 | 2009 | 0.030 |
Why?
|
| Pheochromocytoma | 1 | 1995 | 312 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 5165 | 0.030 |
Why?
|
| Graft Rejection | 1 | 1996 | 866 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 1992 | 345 | 0.020 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2011 | 126 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 2992 | 0.020 |
Why?
|
| Reference Standards | 1 | 2012 | 368 | 0.020 |
Why?
|
| Thoracic Neoplasms | 1 | 1994 | 347 | 0.020 |
Why?
|
| Lung Transplantation | 1 | 1995 | 389 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 1997 | 701 | 0.020 |
Why?
|
| Religion and Medicine | 1 | 1991 | 46 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 754 | 0.020 |
Why?
|
| Leucovorin | 1 | 1992 | 344 | 0.020 |
Why?
|
| Syringomyelia | 1 | 1990 | 20 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 1996 | 789 | 0.020 |
Why?
|
| HLA-B27 Antigen | 1 | 1989 | 8 | 0.020 |
Why?
|
| Biomarkers | 1 | 2021 | 5107 | 0.020 |
Why?
|
| Intubation, Intratracheal | 1 | 1994 | 454 | 0.020 |
Why?
|
| Paraffin | 1 | 2009 | 13 | 0.020 |
Why?
|
| Hysterectomy | 1 | 1994 | 645 | 0.020 |
Why?
|
| Cystectomy | 1 | 1994 | 632 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 1996 | 1444 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 2318 | 0.020 |
Why?
|
| Brain | 1 | 2003 | 4251 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1992 | 1438 | 0.020 |
Why?
|
| Surgical Flaps | 1 | 2015 | 881 | 0.020 |
Why?
|
| Medicare | 1 | 2014 | 933 | 0.020 |
Why?
|
| Calcification, Physiologic | 1 | 2008 | 55 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 1996 | 1313 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1996 | 1437 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2015 | 1858 | 0.020 |
Why?
|
| Clavicle | 1 | 2007 | 66 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2021 | 3534 | 0.020 |
Why?
|
| Physicians | 1 | 1996 | 871 | 0.020 |
Why?
|
| Gene Expression | 1 | 2016 | 3679 | 0.020 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2011 | 268 | 0.020 |
Why?
|
| Quality of Life | 1 | 2022 | 4740 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 1996 | 1184 | 0.020 |
Why?
|
| Recurrence | 3 | 2004 | 4884 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2001 | 5326 | 0.020 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1997 | 1735 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 1991 | 532 | 0.020 |
Why?
|
| Equipment Design | 1 | 2009 | 1207 | 0.020 |
Why?
|
| Glioma | 1 | 1997 | 1969 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 5106 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1991 | 3073 | 0.020 |
Why?
|
| Calcium Carbonate | 1 | 2005 | 28 | 0.020 |
Why?
|
| Child, Preschool | 2 | 1999 | 16930 | 0.020 |
Why?
|
| Punctures | 1 | 1995 | 105 | 0.020 |
Why?
|
| Bronchi | 2 | 1997 | 329 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2006 | 311 | 0.020 |
Why?
|
| HIV Infections | 1 | 1997 | 2157 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2007 | 1432 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2001 | 5237 | 0.010 |
Why?
|
| Oxides | 1 | 2004 | 212 | 0.010 |
Why?
|
| Arsenicals | 1 | 2004 | 204 | 0.010 |
Why?
|
| Aminoglycosides | 1 | 2004 | 235 | 0.010 |
Why?
|
| Women's Health | 1 | 2004 | 203 | 0.010 |
Why?
|
| Colonoscopy | 2 | 1996 | 519 | 0.010 |
Why?
|
| Tretinoin | 1 | 2004 | 621 | 0.010 |
Why?
|
| Nasal Cavity | 1 | 2003 | 147 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 4003 | 0.010 |
Why?
|
| Carcinoma | 1 | 1992 | 2627 | 0.010 |
Why?
|
| Research | 1 | 2003 | 427 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2008 | 2237 | 0.010 |
Why?
|
| Video Recording | 1 | 2002 | 274 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 3417 | 0.010 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2000 | 106 | 0.010 |
Why?
|
| Neoplasms | 1 | 2006 | 15861 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2001 | 6034 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2004 | 2266 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 3539 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 1996 | 5992 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 4507 | 0.010 |
Why?
|
| Pancreas | 1 | 2001 | 744 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 5438 | 0.010 |
Why?
|
| Testicular Diseases | 1 | 1997 | 22 | 0.010 |
Why?
|
| Ileocecal Valve | 1 | 1996 | 3 | 0.010 |
Why?
|
| Pancreatectomy | 1 | 2001 | 696 | 0.010 |
Why?
|
| Ileal Diseases | 1 | 1996 | 27 | 0.010 |
Why?
|
| Cholangiography | 1 | 1996 | 35 | 0.010 |
Why?
|
| Bronchography | 1 | 1996 | 24 | 0.010 |
Why?
|
| Cholelithiasis | 1 | 1996 | 49 | 0.010 |
Why?
|
| Intussusception | 1 | 1996 | 52 | 0.010 |
Why?
|
| Palpation | 1 | 1996 | 51 | 0.010 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 1995 | 20 | 0.010 |
Why?
|
| Sternum | 1 | 1996 | 96 | 0.010 |
Why?
|
| HIV Antibodies | 1 | 1995 | 95 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 1995 | 130 | 0.010 |
Why?
|
| Muscular Diseases | 1 | 1995 | 163 | 0.010 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 1996 | 331 | 0.010 |
Why?
|
| Sheep | 1 | 1994 | 276 | 0.010 |
Why?
|
| Postpartum Period | 1 | 1995 | 262 | 0.010 |
Why?
|
| Duodenum | 1 | 1994 | 170 | 0.010 |
Why?
|
| Prednisone | 1 | 1996 | 1039 | 0.010 |
Why?
|
| Thorax | 1 | 1994 | 230 | 0.010 |
Why?
|
| Hospitals, General | 1 | 1992 | 32 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1995 | 835 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1992 | 170 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2004 | 3397 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1995 | 370 | 0.010 |
Why?
|
| Massachusetts | 1 | 1992 | 144 | 0.010 |
Why?
|
| Graft Survival | 1 | 1996 | 1093 | 0.010 |
Why?
|
| Colon | 1 | 1996 | 689 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1996 | 408 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1996 | 722 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 4519 | 0.010 |
Why?
|
| Ultrasonography, Prenatal | 1 | 1997 | 912 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 1994 | 583 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 1994 | 659 | 0.010 |
Why?
|
| Cross Infection | 1 | 1994 | 548 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1996 | 3033 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 1996 | 872 | 0.010 |
Why?
|
| Logistic Models | 1 | 1996 | 3431 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 1993 | 734 | 0.000 |
Why?
|
| Spinal Cord | 1 | 1990 | 726 | 0.000 |
Why?
|
| Incidence | 1 | 1996 | 5842 | 0.000 |
Why?
|
| Liver | 1 | 1995 | 3124 | 0.000 |
Why?
|
| Hypertension | 1 | 1994 | 1614 | 0.000 |
Why?
|
| Smoking | 1 | 1993 | 2427 | 0.000 |
Why?
|
| Registries | 1 | 1992 | 2238 | 0.000 |
Why?
|
| Child | 2 | 1996 | 30372 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1997 | 8580 | 0.000 |
Why?
|
| Survival Analysis | 1 | 1992 | 9305 | 0.000 |
Why?
|
| Animals | 1 | 1994 | 62824 | 0.000 |
Why?
|